RESVERAC Trademark

Trademark Overview

On Tuesday, December 15, 2015, a trademark application was filed for RESVERAC with the United States Patent and Trademark Office. The USPTO has given the RESVERAC trademark a serial number of 79182066. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, March 17, 2023. This trademark is owned by Aussie Pharma Pty Ltd.. The RESVERAC trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and veterinary preparations for treatment of cellular damage due to oxidating agents, DNA damage due to estrogen initiated cancers, general decay of vascular, skeletal and neuro-muscular system, and vitamin D3 deficiency; medicines for treatment of cellular damage due to oxidating agents, DNA damage due to estrogen initiated cancers, general decay of vascular, skeletal and neuro-muscular system, and vitamin D3 deficiency for human and animal use; dietetic substances, namely, antioxidants, chelating agents and D3 vitamins adapted for medical or veterinary use; dietary supplements for humans and animals; dietary food supplements * none of the aforementioned being for use in relation to ocular, periocular or sight fields *
resverac

General Information

Serial Number79182066
Word MarkRESVERAC
Filing DateTuesday, December 15, 2015
Status709 - CANCELLED - SECTION 71
Status DateFriday, March 17, 2023
Registration Number5033918
Registration DateTuesday, September 6, 2016
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, June 21, 2016

Trademark Statements

Certificate of Correction for RegistrationIn the statement, line 13, after "supplements" "none of the aforementioned being for use in relation to ocular, periocular or sight fields" should be inserted.
Goods and ServicesPharmaceutical and veterinary preparations for treatment of cellular damage due to oxidating agents, DNA damage due to estrogen initiated cancers, general decay of vascular, skeletal and neuro-muscular system, and vitamin D3 deficiency; medicines for treatment of cellular damage due to oxidating agents, DNA damage due to estrogen initiated cancers, general decay of vascular, skeletal and neuro-muscular system, and vitamin D3 deficiency for human and animal use; dietetic substances, namely, antioxidants, chelating agents and D3 vitamins adapted for medical or veterinary use; dietary supplements for humans and animals; dietary food supplements * none of the aforementioned being for use in relation to ocular, periocular or sight fields *
Pseudo MarkRESVER AC
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, March 17, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAussie Pharma Pty Ltd.
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressAU
Party NameAussie Pharma Pty Ltd.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressAU
Party NameAussie Pharma Pty Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressAU

Trademark Events

Event DateEvent Description
Monday, December 18, 2023TOTAL INVALIDATION PROCESSED BY THE IB
Wednesday, November 29, 2023TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Wednesday, November 29, 2023INVALIDATION PROCESSED
Friday, November 17, 2023TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, March 17, 2023CANCELLED SECTION 71
Monday, September 6, 2021COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, November 6, 2020NEW REPRESENTATIVE AT IB RECEIVED
Friday, June 23, 2017INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Tuesday, June 20, 2017PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, December 23, 2016FINAL DECISION TRANSACTION PROCESSED BY IB
Wednesday, December 7, 2016FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, December 7, 2016FINAL DISPOSITION PROCESSED
Tuesday, December 6, 2016FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, October 20, 2016CORRECTION UNDER SECTION 7 ¿ PROCESSED
Thursday, October 20, 2016CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, October 20, 2016LIMITATION FROM THE IB EXAMINED AND ENTERED
Thursday, September 8, 2016LIMITATION OF GOODS RECEIVED FROM IB
Tuesday, September 6, 2016REGISTERED-PRINCIPAL REGISTER
Friday, July 15, 2016NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, June 21, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 21, 2016PUBLISHED FOR OPPOSITION
Wednesday, June 1, 2016NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, June 1, 2016NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, June 1, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, May 13, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, May 13, 2016REFUSAL PROCESSED BY IB
Wednesday, April 20, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, April 19, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, April 19, 2016TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 14, 2016ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, April 14, 2016TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, April 1, 2016NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, April 1, 2016REFUSAL PROCESSED BY MPU
Friday, April 1, 2016NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, March 31, 2016NON-FINAL ACTION WRITTEN
Thursday, March 31, 2016ASSIGNED TO EXAMINER
Saturday, February 20, 2016APPLICATION FILING RECEIPT MAILED
Tuesday, February 16, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, February 11, 2016SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

resverac damage agents dietary skeletal vascular muscular decay deficiency vitamin system